Results 141 to 150 of about 9,532 (171)
Pomalidomide therapy for myeloma
Expert Opinion on Investigational Drugs, 2011 Introduction: The Office of National Statistics (London, UK) has reported 4040 new patients in the year 2007, with an annual age standardized incidence rate of 4.8 per 100,000 population (range 4.7-5.0).
Karthik Ramasamy, Stephen Schey
exaly +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Reactions Weekly, 2014
Pomalidomide (originally CC-4047 or 3-amino-thalidomide) is a derivative of thalidomide that is antiangiogenic and also acts as an immunomodulator. Pomalidomide, as the newest immunomodulatory agent (IMiD), has shown substantial in vitro antiproliferative and proapoptotic effects.
Engelhardt, Monika +3 more
+6 more sources
Pomalidomide (originally CC-4047 or 3-amino-thalidomide) is a derivative of thalidomide that is antiangiogenic and also acts as an immunomodulator. Pomalidomide, as the newest immunomodulatory agent (IMiD), has shown substantial in vitro antiproliferative and proapoptotic effects.
Engelhardt, Monika +3 more
+6 more sources
New synthesis route for the preparation of pomalidomide
Synthetic Communications, 2016 A new route for the preparation of pomalidomide is described in the study. The synthetic procedure starts from 4-nitroisobenzofuran-1,3-dione and 3-aminopiperidine-2,6-dione hydrochloride via a three-step reaction resulting in a total yield of 65% with a
Chengwu Shen, Wenya Wang, Jianqi Li
exaly +2 more sources
Blood, 2013
AbstractThis spotlight review focuses on the second-generation immunomodulatory drug pomalidomide, which was recently approved by the US Food and Drug Administration. This drug was approved for patients with multiple myeloma who have received at least 2 prior therapies, including lenalidomide and bortezomib, and have demonstrated disease progression on
Martha Q, Lacy, Arleigh R, McCurdy
openaire +2 more sources
AbstractThis spotlight review focuses on the second-generation immunomodulatory drug pomalidomide, which was recently approved by the US Food and Drug Administration. This drug was approved for patients with multiple myeloma who have received at least 2 prior therapies, including lenalidomide and bortezomib, and have demonstrated disease progression on
Martha Q, Lacy, Arleigh R, McCurdy
openaire +2 more sources